Savara (NASDAQ:SVRA) Trading 3% Higher Following Analyst Upgrade

Savara Inc (NASDAQ:SVRA)’s stock price was up 3% during trading on Wednesday after Oppenheimer raised their price target on the stock from $9.50 to $11.00. Oppenheimer currently has an outperform rating on the stock. Savara traded as high as $4.45 and last traded at $4.43. Approximately 25,574 shares were traded during trading, a decline of 97% from the average daily volume of 858,414 shares. The stock had previously closed at $4.30.

A number of other equities research analysts have also recently commented on the stock. JMP Securities reissued a “market outperform” rating and set a $8.00 target price on shares of Savara in a research report on Monday, May 6th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Monday, May 13th. Evercore ISI cut their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, May 16th. Finally, Piper Sandler increased their price objective on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $9.17.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Bain Capital Life Sciences Investors LLC boosted its holdings in Savara by 2.3% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after purchasing an additional 332,706 shares during the last quarter. Jennison Associates LLC increased its stake in Savara by 0.3% during the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after buying an additional 26,613 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Savara by 30.9% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock worth $30,008,000 after buying an additional 1,874,000 shares during the period. Vanguard Group Inc. increased its stake in Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after buying an additional 148,673 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Savara by 41.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after buying an additional 746,407 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Performance

The firm’s 50 day moving average is $4.77 and its two-hundred day moving average is $4.59. The stock has a market capitalization of $598.36 million, a PE ratio of -11.70 and a beta of 0.73. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90.

Savara (NASDAQ:SVRA) last issued its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. As a group, research analysts predict that Savara Inc will post -0.41 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.